EGFR and non-small cell lung carcinoma: A number of subsequent studies determined that patients with EGFR-mutant NSCLC had a high likelihood of responding to these TKI, leading to trials in the first-line setting for EGFR-mutant cancer.[7], [8], [9], [10], [11], [12], [13] Four prospective randomized clinical trials studied in Asian populations demonstrated that erlotinib and gefitinib resulted in improved progression-free survival compared to chemotherapy for first line therapy in NSCLC patients with EGFR mutations.[7], [8], [9], [13] Other clinical studies in mixed ethnicity cohorts have concluded with similar results.[10],[12]